MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$72,427K
Proceeds from issuance of
common stock
$19K
Proceeds from sales of
property and equipment
$963K
Net cash provided by
investing activities
$44,302K
Net cash provided by
financing activities
$19K
Canceled cashflow
$29,088K
Net increase
(decrease) in cash
$4,471K
Canceled cashflow
$39,850K
Purchases of marketable
securities
$29,016K
Purchase of property and
equipment
$72K
Stock-based compensation
expense
$2,782K
Non-cash lease expense
$2,526K
Depreciation and
amortization
$1,291K
Other long-term
liabilities
$132K
Prepaid expenses and
other assets
-$76K
Net cash used in
operating activities
-$39,850K
Canceled cashflow
$6,807K
Net loss
-$33,376K
Accounts payable and
accrued expenses
-$5,430K
Deferred revenue
-$4,642K
Operating lease
liabilities, net
-$2,251K
Accretion of discount on
marketable securities
$670K
Gain on sale of fixed
assets
$288K
Back
Back
Cash Flow
source: myfinsight.com
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)